LYR-210 for Chronic Sinusitis

Not currently recruiting at 121 trial locations
LC
Overseen ByLyra Clinical
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called LYR-210 for individuals with chronic sinusitis, a condition that causes long-term sinus inflammation. The goal is to determine if LYR-210 reduces symptoms more effectively than a sham procedure. Participants will receive either the new treatment or the sham. Ideal candidates have chronic sinusitis confirmed by a CT scan and have tried at least two other treatments without success. As a Phase 3 trial, this is the final step before FDA approval, providing participants an opportunity to contribute to a potentially groundbreaking treatment.

Do I need to stop my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team to get a clear answer.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that LYR-210 is generally safe and well-tolerated. In earlier studies, including one lasting 24 weeks, participants using LYR-210 reported only a few side effects. These studies found that LYR-210 was safe at various doses and helped reduce symptoms quickly and for an extended period. Another study showed positive results, with significant symptom improvement compared to a placebo group. Overall, the evidence suggests that LYR-210 is a promising treatment with a good safety record for people with chronic sinusitis.12345

Why do researchers think this study treatment might be promising for chronic sinusitis?

Unlike the standard of care for chronic sinusitis, which typically involves antibiotics, corticosteroids, or surgery, LYR-210 offers a novel approach by delivering a sustained-release medication directly to the nasal cavity. This unique delivery method allows the drug matrix to continuously release the active ingredient over several weeks, potentially reducing inflammation and symptoms more effectively and with fewer systemic side effects. Researchers are excited about LYR-210 because it targets the condition locally and could offer long-term relief with a single administration, making it a promising option for those seeking alternatives to frequent medication or invasive procedures.

What evidence suggests that LYR-210 might be an effective treatment for chronic sinusitis?

Research has shown that LYR-210, which participants in this trial may receive, effectively treats chronic sinusitis. In one study, patients experienced significant symptom relief and reduced inflammation over 24 weeks. The ENLIGHTEN 2 trial demonstrated that LYR-210 provided better results than a sham procedure, another arm in this trial. This treatment involves a small implant placed in the nose that slowly releases medicine to reduce inflammation and ease symptoms. These findings suggest that LYR-210 could offer real relief for those struggling with chronic sinusitis.12346

Are You a Good Fit for This Trial?

This trial is for adults with chronic sinusitis confirmed by a CT scan, who have not had sinus surgery. Participants should be experiencing symptoms like nasal blockage, runny nose, facial pain, or loss of smell for at least 3 months and these should significantly affect their daily life. They must have used steroid nasal sprays for at least 4 weeks.

Inclusion Criteria

Bilateral ethmoid disease confirmed on CT
Mean 3 cardinal symptom (3CS) score
Diagnosed as having CRS
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single administration of LYR-210 or a sham procedure for 24 weeks

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Background therapy
  • LYR-210
  • Sham procedure control
Trial Overview The study is testing LYR-210 against a sham procedure to see if it's better in treating chronic sinusitis when added to regular background therapy. It's a large-scale phase III trial where participants are randomly assigned to either the test drug or control group without knowing which one they're getting.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LYR-210Experimental Treatment2 Interventions
Group II: Sham procedure controlPlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Lyra Therapeutics

Lead Sponsor

Trials
5
Recruited
520+

Citations

Efficacy and Safety of LYR-210 for the Treatment ...This is a 24-week, multicenter, phase III, randomized, blinded, controlled, parallel group with a 24-week treatment period to evaluate the efficacy and ...
Results of LANTERN Phase 2 randomized controlled studyThe treatment effect of LYR‐210 was evaluated over 24 weeks based on patient symptom improvement, reduction in sinonasal inflammation, and reduction in the need ...
News Release - Investor Relations - Lyra Therapeutics, Inc.The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control.
Study: LYR-210 Shows Promise in Chronic Rhinosinusitis ...New findings show LYR-210's potential to significantly alleviate chronic rhinosinusitis symptoms, offering hope for patients with nasal inflammation and polyps.
Lyra Therapeutics Announces Clinical Plan for LYR-210 and ...The 24-week endpoints in the ENLIGHTEN trials assess LYR-210's long-acting therapeutic effect as a bioresorbable sinonasal implant designed to ...
Lyra Therapeutics, Inc. Study LYR-210-2021-004For safety analysis incorporating the safety extension phase, the above safety endpoints will be summarized from Day 1 through Week 48 for the LYR-210 to LYR- ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security